Independent · non-commercial · publishes on a quarterly cycle|Current cycle 2026 Q3
Methodology|Interests|Funding|Corrections
Compound Evidence InstituteEvidence synthesis · established 2023Graded assessments of compounds, trials, methods and supply
Document set current to 30 July 2026
Bibliographic record

Efficacy and safety of oral small molecule glucagon-like peptide 1 receptor agonist danuglipron for glycemic…

Saxena AR, Frias JP, Brown LS, Gorman DN, Vasas S, Tsamandouras N, Birnbaum MJ. JAMA Network Open 2023

Document identifier
CEI-BR-100
Series
Bibliographic record
Version
1.0
Published
30 Jul 2026
Last reviewed
30 Jul 2026
Certainty
Not rated

§1Bibliographic record

§1.1Record

Authors
Saxena AR, Frias JP, Brown LS, Gorman DN, Vasas S, Tsamandouras N, Birnbaum MJ
Title
Efficacy and safety of oral small molecule glucagon-like peptide 1 receptor agonist danuglipron for glycemic control among patients with type 2 diabetes: a randomized clinical trial
Source
JAMA Network Open
Year
2023
Volume, issue, pages
6(5):e2314493
Digital object identifier
10.1001/jamanetworkopen.2023.14493
PubMed identifier
37237090
Record type
Journal article
Institute identifier
CEI-BR-100

§1.2Institute documents citing this record

Table 1. Documents in the Institute set that cite this record.

DocumentSeries
Monograph: DanuglipronCompound monograph
1 citing document.

§1.3Subject tags

danuglipron t2dm

Compound Evidence Institute · CEI-BR-100 · https://compoundevidence.com/bibliography/saxena2023/ · retrieved 30 July 2026
Nothing published by the Institute is medical advice, a diagnosis, a prescription, a treatment recommendation or a purchasing recommendation. Compounds supplied for research use are not approved for human or veterinary use in any jurisdiction, and a favourable analytical assessment of a supplier is not a statement that any product is safe or effective. The Institute publishes certainty ratings and never recommendations. No telephone number, messaging handle or ordering channel appears anywhere on this site.